Figures & data
Table 1 Summary of treatment compliance across the two 3-month placebo-controlled studies (114117/114418; ITT population)
Table 2 Summary of treatment compliance across the two 6-month active comparator studies (113360/113374; ITT population)
Table 3 Ellipta™ dry powder inhaler correct use, ease of use, and remaining dose determination (3-month placebo-controlled studies, 114417/114418; ITT population)
Table 4 Inhaler preference outcomes from using the COPD Device Preference Questionnaire in the two Phase IIIa active comparator studies (113360/113374; ITT population)
Table S1 Summary of treatment compliance in the Phase IIIb active comparator study (117115; ITT population)
Table S2 Inhaler preference outcomes from using the COPD Device Preference Questionnaire in the Phase IIIb active comparator study (intent-to-treat population)